After recent Pharmacovigilance legislations, SMi's conference will present the successes and failures since its implementation. 2012-2013 can be seen as year of significant change with regards to Pharmacovigilance practices and this topic has never been more of a focus for Pharmaceutical companies across the board.
With concerns occurring across the board in relation to PV auditing, companies face the challenge of understanding the key considerations when presenting to auditors. Unravel the challenges in compiling and presenting the new PSUR to external regulatory bodies and determine what these regulatory bodies have learnt in the wake of its recent introduction.
Join SMi as they look tackle these issues and many more at a summit that promises to be a must see event.
With concerns occurring across the board in relation to PV auditing, companies face the challenge of understanding the key considerations when presenting to auditors. Unravel the challenges in compiling and presenting the new PSUR to external regulatory bodies and determine what these regulatory bodies have learnt in the wake of its recent introduction.
Join SMi as they look tackle these issues and many more at a summit that promises to be a must see event.
